Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities
Originally developed to manage type 2 diabetes, semaglutide has been FDA-approved for chronic weight management and available through reputable wellness clinics as well as providers across the country
According to the National Institute for Health and Care Excellence (NICE) guideline NG28, GLP-1 receptor agonists like Ozempic are typically recommended as part of triple therapy regimens for type 2 diabetes under specific criteria, including BMI considerations and when other treatments have not achieved glycaemic targets
The most commonly reported side effects were gastrointestinal, such as nausea, vomiting, diarrhoea, or constipation
preliminary sex-specific meta-analyses continue to be published)
Cmax: maximum concentration